The trial was designed to evaluate the effect of MC-1, versus placebo, on the incidence of cardiovascular death or nonfatal myocardial infarction up to and including 30 days following coronary artery bypass graft or CABG surgery.
Based on the results, the company does not plan on submitting an application for MC-1 marketing approval to the FDA for the CABG indication at this time.